Vedanta Biosciences recently reported the initiation of treatment for the initial participant in the COLLECTiVE202 Phase 2 investigation of VE202.

BridgeBio Pharma and National Resilience Inc., which focus on genetic diseases, cancer pharmaceuticals, and tech-driven biomanufacturing respectively, announced a partnership to develop and produce BBP-812 and BBP-631, gene therapies for Canavan disease and congenital adrenal hyperplasia.

Disc Medicine has revealed the start of a Phase 1 trial for DISC-3405 (formerly MWTX-003) with healthy participants.

Kineta, Inc., a clinical-stage biotech firm specializing in unique cancer immunotherapies, has shared updates on their ongoing Phase 1/2 clinical trial of KVA12123 for advanced solid tumor patients.

Clarity Pharmaceuticals proudly announces the initial patient dosing in their 64Cu/67Cu SAR-Bombesin Phase I/II theranostic trial for patients with metastatic castrate resistant prostate cancer.

REGENXBIO Inc. disclosed further provisional safety information and preliminary effectiveness results from the phase I/II AFFINITY DUCHENNE™ study of RGX-202 aimed at treating Duchenne Muscular Dystrophy.

Transcenta Holding Limited states that it has received the green light from FDA to continue with TranStar 301,This trial is conducted for Osemitamab (TST001) used together with Nivolumab and chemotherapy.

Syndax Pharmaceuticals has reported encouraging preliminary figures following a protocol-defined collective examination of the essential AUGMENT-101 study on revumenib, a front-runner in the class of menin inhibitors.

SOLA Biosciences is set to share its promising preliminary proof-of-concept data for SOL-257, a specific gene therapy aimed at misfolded TDP-43 in ALS.

Vertex Pharmaceuticals Incorporated presented extensive data related to the patients treated in sections A and B of their Phase 1/2 clinical assessment trial of VX-880.

Purple Biotech Ltd. shares clinical insights from its dose amplification segment of the Phase 1/2 trial of NT219.

Ocular Therapeutix has publicized the start of its premiere primary clinical trial to examine OTX-TKI, a proprietary axitinib intravitreal implant, for tackling wet age-related macular degeneration.